TM3 Therapeutics Published In Vivo Proof of Concept Data for Treatment of PKAN
TM3 Therapeutics, a spin-off of ACIES BIO, is a biopharmaceutical company focused on developing metabolite replacement therapies for rare, genetic neurological diseases.
TM3 Therapeutics announced the publication of novel preclinical data on its lead compound, TM-1803 (referred in the publication as P-PantSAc), in mice and in other models of Pantothenate Kinase-Associated Neurodegeneration (PKAN). The lead candidate was shown to have serum-stability, low toxicity, and efficacy in mitigating the phenotypes associated with the disease. The paper titled, “Acetyl-4’-phosphopantetheine is stable in serum and prevents phenotypes induced by pantothenate kinase deficiency” can be accessed in the online edition of the journal, Scientific Reports published yesterday, September 12, 2017.
You can read the whole announcement on BusinessWire.
This brings TM3 Therapeutics another step closer to clinical trials for TM-1803. Congratulations!